Mariner’s Cymabay Therapeutics CBAY Stock Holding History

Mariner’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-12,000	Closed	-$23K	–	567
2015 Q3	$23K	Buy	+12,000	New	+$32.7K	﹤0.01%	522

Other funds holding CBAY

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Mariner's CBAY Position: Q4 2015 in Review

Mariner sold out of Cymabay Therapeutics (CBAY) in Q4 2015, closing a stake of 12,000 shares — an estimated $23K sold.

Mariner first reported a position in CBAY in Q3 2015 and held it in 1 quarter. The position peaked at $23K in Q3 2015. 29 funds tracked by Wall St. Rank hold CBAY as of Q4 2015.

Mariner reported no remaining Cymabay Therapeutics position as of Q4 2015 after selling out during the quarter.
Mariner sold 12,000 Cymabay Therapeutics shares in Q4 2015, an estimated $23K.
Mariner first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 1 quarter.
Mariner's Cymabay Therapeutics position peaked at $23K in Q3 2015.
29 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2015.

Based on Mariner's 13F filing for Q4 2015, filed 16 Feb 2016.